Nanoparticle drug delivery system for restenosis

Advanced Drug Delivery Reviews

Volumn 24, Issue 1, 1997, Pages 63-85

  Labhasetwar, Vinod ^a   Song, Cunxian ^a   Levy, Robert J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

angioplasty; intra arterial localization; local drug delivery; polymers; reocclusion; smooth muscle cell proliferation; thrombosis

Indexed keywords

AGENTS; BIOCOMPATIBILITY; BLOOD VESSELS; CARDIOLOGY; CELLS; DISEASES; DRUG DOSAGE; MUSCLE; NANOSTRUCTURED MATERIALS; ORGANIC POLYMERS;

ANGIOPLASTY; INTRA-ARTERIAL LOCALIZATION; LOCAL DRUG DELIVERY; PROLIFERATION; REOCCLUSION; RESTENOSIS; SMOOTH MUSCLE CELL; THROMBOSIS;

CONTROLLED DRUG DELIVERY;

ALBUMIN; ANTICOAGULANT AGENT; ANTIPROLIFERATIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBOCYTIC AGENT; CASEIN; DEXAMETHASONE; DRUG CARRIER; ETHYLENE VINYL ACETATE COPOLYMER; GELATIN; HEPARIN; INSULIN; LECTIN; MACROGOL; NANOPARTICLE; POLY(CYANOACRYLATE); POLY(METHYL METHACRYLATE); POLYANHYDRIDE; POLYCAPROLACTONE; POLYESTER; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POLYSACCHARIDE; POLYVINYL ALCOHOL; U 86983; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ARTERY WALL; BIOCOMPATIBILITY; CATHETER; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG PENETRATION; DRUG TARGETING; HUMAN; IMPLANT; INTRAARTERIAL DRUG ADMINISTRATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; STENT; THROMBOSIS;

EID: 0031568939     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00483-8     Document Type: Review

References (191)

1. [1] Haudenschild, C.C. (1993) Pathobiology of restenosis after angioplasty. Am. J. Med. 94. 40S-44S.
2. [2] Lovqvist, A., Emanuelsson, H., Nilsson, J., Lundqvist, H. and Carlsson, J. (1993) Pathophysiological mechanisms for restenosis following coronary angioplasty: possible preventive alternatives. J. Intern. Med. 233, 215-226.
3. [3] Koster, R., Windstetter, U., Uberfuhr, P., Baumann, G., Nikol, S. and Hofling, B. ( 1995) Enhanced migratory activity of vascular smooth muscle cells with high expression of platelet-derived growth factor A and B. Angiology 46, 99-106.
4. [4] Wilcox, J.N. (1991) Thrombin and other potential mechanisms underlying restenosis. Circulation 84, 432-435.
5. [5] Wilcox, J.N. (1993) Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. Am. J. Cardiol. 72, 88E-95E.
6. [6] Wilcox, J.N. and Blumenthal, B.F. (1995) Thrombotic mechanisms in atherosclerosis: potential impact of soy proteins. J. Nutr. 125, 631S-638S.
7. [7] Popma, J.J., Califf, R.M. and Topol, E.J. (1991) Clinical trials of restenosis after coronary angioplasty [editorial]. Circulation 84, 1426-1436.
8. [8] Carrozza, J.J., Kuntz, R.E., Fishman, R.F. and Baim, D.S. (1993) Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann. Intern. Med. 118, 344-349.
9. [9] Epstein, S.E., Speir, E., Unger, E.F., Guzman, R.J. and Finkel, T. (1994) The basis of molecular strategies for treating coronary restenosis after angioplasty. J. Am. Coll. Cardiol. 23, 1278-1288.
10. [10] Finkel, T. and Epstein, S.E. (1995) Gene therapy for vascular disease. FASEB J. 9, 843-851.
11. [11] Herrman, J.P., Hermans, W.R., Vos, J. and Serruys, P.W. (1993) Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Parts I and II). Drugs 46, 18-52; 249-262.
12. [12] Morishita, R., Gibbons, G.H., Horiuchi, M., Ellison, K.E., Nakama, M., Zhang, L., Kaneda, Y., Ogihara, T. and Dzau, V.J. (1995) A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA 92, 5855-5859.
13. [13] Muller, D.W. (1994) Gene therapy for cardiovascular disease [editorial]. Br. Heart J. 72, 309-312.
14. [14] Morris, J., Wishka, D.G., Lin, A.H., Humphrey, W.R., Wiltse, A.L., Gammill, R.B., Judge, T.M., Bisaha, S.N., Olds, N.L., Jacob, C.S., Bergh, C.L., Cudahy, M.M., Williams. D.J., Nishizawa, E.E., Thomas, E.W., Gorman, R.R., Benjamin, C.W. and Shebuski, R.J. (1993) Synthesis and biological evaluation of antiplatelet 2-aminochromones. J. Med. Chem. 36, 2026-2032.
15. [15] Nabel, E.G., Plautz, G. and Nabel, G.J. (1990) Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249, 1285-1288.
16. [16] Nabel, E.G. (1992) Direct gene transfer into the arterial wall. J. Vasc. Surg. 15, 931-932.
17. [17] Nabel, E.G., Pompili, V.J., Plautz, G.E. and Nabel, G.J. (1994) Gene transfer and vascular disease. Cardiovasc. Res. 28, 445-455.
18. [18] Nabel, E.G. (1995) Gene therapy for cardiovascular disease. Circulation 91, 541-548.
19. [19] Riessen, R., Rahimizadeh, H., Blessing, E., Takeshita, S., Barry, J.J. and Isner, J.M. (1993) Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum. Gene Ther. 4, 749-758.
20. [20] Fuster, V., Falk, E., Fallon, J.T., Badimon, L., Chesebro, J.H. and Badimon, J.J. (1995) The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb. Haemost. 74, 552-559.
21. [21] Marmur, J.D., Merlini, P.A., Sharma, S.K., Khaghan, N., Torre, S.R., Israel, D.H., Ardissino, D. and Ambrose, J.A. (1994) Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J. Am. Coll. Cardiol. 24, 1484-1491.
22. [22] Mathias, K. (1991) Local thrombolysis for salvage of occluded bypass grafts. Semin. Thromb. Hemost. 17, 14-20.
23. [23] Bennett, MR., Anglin, S., McEwan, J.R., Jagoe, R., Newby. A.C. and Evan, G.I. (1994) Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest. 93, 820-828.
24. [24] Epstein, S.E., Speir, E. and Finkel, T. (1993) Do antisense approaches to the problem of restenosis make sense? [editorial]. Circulation, 88, 1351-1353.
25. [25] Edelman, E.R., Simons, M., Sirois, M.G, and Rosenberg, R.D. (1995) c-myc in vasculoproliferative disease. Circ. Res. 76, 176-182.
26. [26] Feldman, L.J. and Isner, J.M. (1995) Gene therapy for the vulnerable plaque. J. Am. Coll. Cardiol. 26, 826-835.
27. [27] Marmur, J.D., Poon, M., Rossikhina, M. and Taubman, M.B. (1992) Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. Circulation 86, III53-III60.
28. [28] Ohno, T., Gordon, D., San, H., Pompili, V.J., Imperiale, M.J., Nabel, G.J. and Nabel, E.G. (1994) Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265, 781-784.
29. [29] Wilensky, R.L., March, K.L., Gradus-Pizlo, I., Spaedy, A.J. and Hathaway, D.R. (1993) Methods and devices for local drug delivery in coronary and peripheral arteries. Trends Cardiovasc. Med. 3, 163-170.
30. [30] De Scheerder, LK., Wilczek, K.L., Verbeken, E.V., Vandorpe, J., Lan, P.N., Schacht, E., De, G.H. and Piessens, J. (1995) Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 114, 105-114.
31. [31] Foley, J.B., Penn, LM., Brown, R.I., Murray, P.N., White, J., Galligan, L. and MacDonald, C. (1993) Safety, success and restenosis after elective coronary implantation of the PalmazSchatz stent in 100 patients at a single center. Am. Heart J. 125, 686-694.
32. [32] Kuntz, R.E., Gibson, C.M., Nobuyoshi, M. and Baim, D.S. (1993) Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J. Am. Coll. Cardiol. 21, 15-25.
33. [33] Lambert, T.L., Dev. V., Rechuvia, E., Forrester, J.S., Litvack, F. and Eigler, N.L. (1994) Localized arterial wall drug delivery from a polymer-coated removable metallicstent. Kinetics, distribution, and bioactivity of forskolin. Circulation 90, 1003-1011.
34. [34] Mitchel, J.F. and McKay, R.G. (1995) Treatment of acuteslent thrombosis with local urokinase therapy using catheter-based, drug delivery systems: a case report. Cathet. Cardiovasc. Diagn. 34, 149-154.
35. [35] Buchwald, A.B., Sandrock, D., Unterberg, C., Ebbecke, M., Nebendahl, K., Luders, S., Munz, D.L. and Wiegand, V. (1993) Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J. Am. Coll. Cardiol. 21, 249-254.
36. [36] Buchwald, A.B., Werner, G.S., Unterberg, C., Voth, E., Kreuzer, H. and Wiegand, V. (1992) Restenosis after excimer laser angioplasty of coronary stenoses and chronic total occlusions. Am. Heart J. 123, 878-885.
37. [37] Douek, P.C., Correa, R., Neville, R., Unger, E.F., Shou, M., Banai, S., Ferrans, V.J., Epstein, S.E., Leon, M.B. and Bonner, R.F. (1992) Dose-dependent smooth muscle cell proliferation induced by thermal injury with pulsed infrared lasers. Circulation 86, 1249-1256.
38. [38] Israel, D.H., Murmur, J.D. and Sanborn, T.A. (1991) Excimer laser-facilitated balloon angioplasty of a nondilatable lesion. Am. Coll. Cardiol. 18, 1118-1119.
39. [39] McEwan, J., Henney, A. and Humphries, S. (1994) Vascular disease: the next target for local molecular therapeutics [editorial]. Br. Med. J. 308, 995-996.
40. [40] Lincoff, A.M., Topol, E.J. and Ellis, S.G. (1994) Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation 90, 2070-2084.
41. [41] Riessen, R. and Isner, J.M. (1994) Prospects for site-specific delivery of pharmacologic and molecular therapies. J. Am. Coll. Cardiol. 23, 1234-1244.
42. [42] Serruys, P.W., Herrman, J.P. Simon, R., Rutsch, W., Bode, C., Laarman, G.J., van, D.R., van den Bos, A., Umans, V.A., Fox, K.A. and Helvetica Investigators (1995) A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med. 333, 757-763.
43. [43] Garcia, R., Saroyan, R.M., Senkowsky, J., Smith, F. and Kerstein, M. (1990) Intraoperative intra-arterial urokinase infusion as an adjunct to Fogarty catheter embolectomy inacute arterial occlusion. Surg. Gynecol. Obstet. 171, 201-205.
44. [44] Edelman, E.R., Adams, D.H. and Karnovsky, M.J. (1990) Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc. Natl. Acad. Sci. USA 87, 3773-3777.
45. [45] Edelman, E.R., Nugent, M.A. and Karnovsky, M.J. (1993) Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl. Acad. Sci. USA 90, 1513-1517.
46. [46] Edelman, E.R. and Karnovsky, M.J. (1994) Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 89, 770-776.
47. [47] Nathan, A., Nugent, M.A. and Edelman, E.R. (1995) Tissue engineered perivascular endothelial cell implants regulate vascular injury. Proc. Natl. Acad. Sci. USA 92, 8130-8134.
48. [48] Okada, T., Bark, D.H. and Mayberg, M.R. (1989) Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. Neurosurgery 25, 892-898.
49. [49] Villa, A.E., Guzman, L.A., Chen, W., Golomb, G., Levy, R.J. and Topol, E.J. (1994) Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J. Clin. Invest. 93, 1243-1249.
50. [50] Villa, A.E., Guzman, L.A., Poptic, E.J., Labhasetwar, V., D'Souza, S., Farrell, C.L., Plow, E.F., Levy, R.J., DiCorleto, P.E. and Topol, E.J. (1995) Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res. 76, 505-513.
51. [51] Simons, M., Edelman, E.R., DeKeyser, J.L., Langer, R. and Rosenberg, R.D. (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
52. [52] Simons, M., Edelman, E.R. and Rosenberg, R.D. (1994) Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. 93, 2351-2356.
53. [53] Lincoff, A.M., Furst, J.G., Ellis, S.G. and Topol, E.J. (1994) Sustained local drug delivery by a novel intravascular eluting stent to prevent restenosis in the porcine coronary artery [abstract]. J. Am. Coll. Cardiol. 23, 18A.
54. [54] Jeong, M.H., Owens, W.G., Staab, M.E., Srivatsa, S.S., Gregoire, J., Wen, D., Sangiorgi, G., Pompili, V.J., Stewart, M.L., Camrud, A.R., Arndt, L. and Schwartz, R.S. (1995) Does heparin release coating of the Wallstent limit thrombosis and platelet deposition? Results in a porcine carotid injury model [abstract]. Circulation 92, 117.
55. [55] Azrin, M.A., Mitchel, J.F., Fram, D.B., Pedersen, C.A., Cartun, R.W., Barry, J.J., Bow, L.M., Waters, D.D. and McKay, R.G. (1994) Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons. Circulation 90, 433-441.
56. [56] Fram, D.B., Aretz, T., Azrin, M.A., Mitchel, J.F., Samady, H., Gillam, L.D., Sahatjian, R., Waters, D. and McKay, R.G. (1994) Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion. J. Am. Coll. Cardiol. 23, 1570-1577.
57. [57] Mitchel, J.F., Azrin, M.A., Fram, D.R., Hong, M.K., Wong, S.C., Barry, J.J., Bow, L.M., Curley, T.M., Kieman, F.J., Waters, D.D., Leon, M.B. and McKay, R.G. (1994) Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons. Circulation 90, 1979-1988.
58. [58] Nunes, G.L., Thomas, C.N., Hanson, S.R., Barry, J.J., King, S.B. and Scott, N.A. (1995) Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel-coated balloon. Circulation 92, 1697-1700.
59. [59] Steg, P.G., Feldman, L.J., Scoazec, J.Y., Tahlil, O., Barry, J.J., Boulechfar, S., Ragot, T., Isner, J.M. and Perricaudet. M. (1994) Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation 90, 1648-1656.
60. [60] Fernandez, O.A., Meyer, B.J., Mailhac, A., Falk, E., Badimon, L., Fallon, J.T., Fuster, V., Chesebro, J.H. and Badimon, J.J. ( 1994) A new approach for local intravascular drug delivery. Iontophoretic balloon. Circulation 89, 1518-1522.
61. [61] Consigny, P.M. and Miller, K.T. (1994) Drug delivery into the arterial wall: a time-course study with use of alipophilic dye. J. Vasc. Intervent. Radiol. 5, 731-737.
62. [62] Martin, M. and Fiebach, B.J. (1991) Short-term ultrahigh streptokinase treatment of chronic arterial occlusions and acute deep vein thromboses. Semin. Thromb. Hemost. 17, 21-38.
63. [63] McKay, R.G., Fram, D.B., Hirst, J.A., Kiernan, F.J., Primiano, C.A., Rinaldi, M.J., Azrin, M.A., Mitchel, J.F. and Waters, D.D. (1994) Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch catheter. Cathet. Cardiovasc. Diagn. 33, 181-188.
64. [64] Meyer, B.J., Fernandez, O.A., Mailhac, A., Falk, E., Badimon, L., Michael, A.D., Chesebro, J.H., Fuster, V. and Badimon, J.J. (1994) Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 90, 2474-2480.
65. [65] Moreyra, A.E., Macris, A., Kostis, J.B. and Scholz, P. (1990) Coronary perfusion catheter: its effectiveness in an experimental model of acute coronary occlusion. Am. Heart J. 120, 1031-1038.
66. [66] Pitney, M.R., Cumpston, N., Mews, G.C., Cope, G.D. and Gibbons, F. (1992) Use of twenty-four hour infusions of intracoronary tissue plasminogen activator to increase the application of coronary angioplasty. Cathet. Cardiovasc. Diagn. 26, 255-259.
67. [67] Rand, M.L., Groves, H.M. Packham, M.A., Mustard, J.F. and Kinlough, R.R. (1990) Acute administration of ethanol to rabbits inhibits thrombus formation induced by indwelling aortic catheters. Lab. Invest. 63, 742-745.
68. [68] Asahara, T., Bauters, C., Pastore, C., Kearney, M., Rossow, S., Bunting, S., Ferrara, N., Symes, J.F. and Isner, J.M. (1995) Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91, 2793-2801.
69. [69] Labhasetwar, V., Underwood, T., Heil, R.J., Gallagher, M., Langberg, J. and Levy, R.J. (1994) Epicardial administration of ibutilide from polyurethane matrices: effects on defibrillation threshold and electrophysiologic parameters. J. Cardiovasc. Pharmacol. 24, 826-840.
70. [70] Labhasetwar, V., Underwood, T., Schwendeman, S.P. and Levy, R.J. (1995) Iontophoresis for modulation of cardiac drug delivery in dogs. Proc. Natl. Acad. Sci. USA 92, 2612-2616.
71. [71] Levy, R.J., Wolfrum, J., Schoen, F.J., Hawley, M.A., Lund, S.A. and Langer, R. (1985) Inhibition of calcification of bioprosthetic heart valves by local controlled-released iphosphonate. Science 228, 190-192.
72. [72] Golomb, G., Dixon, M., Smith, M.S., Schoen, F.J. and Levy, R.J. (1987) Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicons-matrices via drug solubility and membrane coating. J. Pharm. Sci. 76, 271-276.
73. [73] Bolling, S.F., Lin, H., Annesley, T.M., Boyd, J.A., Gallagher, K.P. and Levy, R.J. (1991) Local cyclosporine immunotherapy of heart transplants in rats enhances survival. J. Heart Lung Transplant. 10, 577-583.
74. [74] Stokes, K.B., Graf, J.E. and Wiebusch, W.A. (1982) Drug editing electrodes-improved pacemaker performance. IEEE 13, 499-502.
75. [75] Stokes, K.B., Knett, J.M., Gornick, C.A., Betloff, B.L.S. and Benditt, D.G. (1983) Low threshold cardiac pacing electrodes. IEEE 5, 100-103.
76. [76] Toray Industries Inc., Product information, Chuo-ku, Tokyo.
77. [77] Torchilin, V.P. (1995) Long-circulating drug delivery systems [eitorial]. Adv. Drug Deliv. Rev. 16, 125-126.
78. [78] Papisov, M.I. (1995) Model in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo). Adv. Drug Deliv. Rev. 16, 127-139.
79. [79] Torchilin, V.P. and Trubetskoy, V.S. (1995) Which polymers can make nanoparticle drug carriers long-circulating? Adv. Drug Deliv. Rev. 16, 141-155.
80. [80] Moghimi, S.M. (1995) Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. Adv. Drug Deliv. Rev. 16, 183-193.
81. [81] Stolnik, S. Illum, L. and Davis, S.S. (1995) Long circulationg microparticulate drug carriers. Adv. Drug Deliv. Rev. 16, 195-214.
82. [82] Gref, R., Domb, A., Quellec, P., Muller, R.H., Verbavatz, J.M. and Langer, R. (1995) The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 16, 215-233.
83. [83] Weissleder, R., Bogdanov, A., Neuwelt, E.A. and Papisov, M. (1995) Long-circulating iron oxides for MR imaging. Adv. Drug Deliv. Rev. 16, 321-334.
84. [84] Bogdanov, A., Jr., Weissleder, R. and Brady, T.J. Long-circulating blood pool imaging agents. Adv. Drug Deliv. Rev. 16, 335-348.
85. [85] Kreuter, J. (1992) Nanoparticles-preparation and applications. Microcapsules and Nanoparticles in Medicine and Pharmacy, Max Bonbrow (Ed.), CRC Press, London, pp. 125-148.
86. [86] Kreuter, J. (1978) Nanoparticles and nanocapsules - new dosage forms in the nanometer size range. Pharm. Acta Helv. 53, 33-39.
87. [87] Kreuter, J. (1983) Evaluation of nanoparticles as drug-delivery systems. III. Materials, stability, toxicity,possibilities of targeting, and use. Pharm. Acta Helv. 58, 242-250.
88. [88] Kreuter, J. (1985) Poly(alkyl acrylate) nanoparticles. Methods Enzymol. 112, 129-138.
89. [89] Kreuter, J. (1988) Possibilities of using nanoparticles as carriers for drugs and vaccines. J. Microencapsulation 5, 115-127.
90. [90] Kreuter, J. (1994) Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinetics 19, 253-256.
91. [91] Kreuter, J., Nefzger, M., Liehl, E., Czok, R. and Voges, R. (1983) Distribution and elimination of poly(methyl methacrylate) nanoparticles after subcutaneous administration to rats. J. Pharm. Sci. 72, 1146-1149.
92. [92] Heller, J. (1993) Polymers for controlled parenteral delivery of peptides and proteins. Adv. Drug Del. Rev 10, 163-204.
93. [93] Labhasetwar, V. and Dorle, A.K. (1990) Nanoparticles-a colloidal drug delivery system for primaquine and metronidazole. J. Control. Release 12, 113-119.
94. [94] Couvreur, P. and Puisieux, F. (1993) Nano-and microparticles for the delivery of polypeptides and proteins. Adv. Drug Del. Rev. 10, 141-162.
95. [95] Bertling, W.M., Gareis, M., Paspaleeva, V., Zimmer, A., Kreuter, J., Nurnberg, E. and Harrer, P. (1991) Use of liposomes, viral capsids, and nanoparticles as DNA carriers. Biotechnol. Appl. Biochem. 13, 390-405.
96. [96] Lescure, F., Seguin, C., Breton, P., Bourrinet, P., Roy, D. and Couvreur, P. (1994) Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles. Pharm. Res. 11, 1270-1277.
97. [97] Niwa, T., Takeuchi, H., Hino, T., Kunou, N. and Kawashima, Y. (1994) In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J. Pharm. Sci. 83, 727-732.
98. [98] Allemann, E., Leroux, J.C., Gurny, R. and Doelker, E. (1993) In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm. Res. 10, 1732-1737.
99. [99] Arai, K., Takayama, K., Nambu, Y., Nambu, N., Ueda, H., Machida, Y. and Nagai, T. (1987) Preparation of polylactic acid-polylipoic acid nanospheres as drug targeting carriers. Drug Des. Deliv. 2, 109-120.
100. [100] Douglas, S.J., Davis, S.S. and Illum, L. (1987) Nanoparticles in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 3, 233-261.
101. [101] Lenaerts, V., Raymond, P., Juhasz, J., Simard, M.A. and Jolicoeur, C. (1989) New method for the preparation of cyanoacrylic nanoparticles with improved colloidal properties. J. Pharm. Sci. 78, 1051-1052.
102. [102] Lin, W., Coombes, A.G., Davies, M.C., Davis, S.S. and Illum, L. (1993) Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J. Drug Target. 1, 237-243.
103. [103] Lin, W., Coombes, A.G., Garnett, M.C., Davies, M.C., Schacht, E., Davis, S.S. and Illum, L. (1994) Preparation of sterically stabilized human serum albumin nanospheres using a novel Dextranox-MPEG crosslinking agent. Pharm. Res. 11, 1588-1592.
104. [104] Marty, J.J., Oppenheim, R.C. and Speiser, P. (1978) Nanoparticles - a new colloidal drug delivery system. Pharm. Acta Helv. 53, 17-23.
105. [105] Maruyama, A., Ishihara, T., Adachi, N. and Akaike, T. (1994) Preparation of nanoparticles bearing high density carbohydrate chains using carbohydrate-carrying polymers as emulsifier. Biomaterials 15, 1035-1042.
106. [106] Verrecchia, T., Huve, P., Bazile, D., Veillard, M., Spenlehauer, G. and Couvreur, P. (1993) Adsorption/desorption of human serum albumin at the surface of poly(lactic acid) nanoparticles prepared by a solvent evaporation process. J. Biomed. Mater. Res. 27, 1019-1028.
107. [107] Speiser, P.P. (1991) Nanoparticles and liposomes: a state of the art. Methods Find. Exp. Clin. Pharmacol. 13, 337-342.
108. [108] Brasseur, F., Couvreur, P., Kante, B., Deckers, P.L., Roland, M., Deckers, C. and Speiser, P. (1980) Actinomycin D adsorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor. Eur. J. Cancer. 16, 1441-1445.
109. [109] Brasseur, F., Couvreur, P., Kante, B., Deckers, P.L., Roland, M., Deckers, C. and Speiser, P. (1980) Actinomycin D absorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor. Eur. J. Cancer 16, 1441-1445.
110. [110] Astier, A., Doat, B., Ferrer, M.J., Benoit, G., Fleury, J., Rolland, A. and Leverge, R. (1988) Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. Cancer Res. 48, 1835-1841.
111. [111] Bennis, S., Robert, J., Nemati, F., Dubernet, C. and Couvreur, P. (1992) Enhanced toxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumoral cells in culture [abstract]. Proc. Annu. Meeting Am. Assoc. Cancer Res. 33, A2846.
112. [112] Bennis, S., Chapey, C., Couvreur, P. and Robert, J. (1994) Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur. J. Cancer 30A, 89-93.
113. [113] Boutan, L.A., Kattan, J., Droz, J.P., Rougier, P., Vranckx, H., Grognet, J.M., Marino, J.P., Sancho, G.H. and Couvreur, P. (1991) Phase I clinical trial of doxorubicin (dox) carried by polyisohexyl cyanoacrylate nanoparticles (pihca) [abstract]. Proc. Annu. Meeting Am. Soc Clin. Oncol., A323.
114. [114] Carpignano, R., Gasco, M.R. and Morel, S. (1991) Optimization of doxorubicine incorporation and of the yield of polybutylcyanacrylate nanoparticles. Pharm. Acta Helv. 66, 28-32.
115. [115] Chiannilkulchai, N., Driouich, Z., Benoit, J.P., Parodi, A.L. and Couvreur, P. ( 1989) Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. Sel. Cancer Ther. 5, 1-11.
116. [116] Couvreur, C., Roblot-Treupel, L., Poupon, M.F., Brasseur, F. and Puisieux, F. (1990) Nanoparticles as microcarriers for anticancer drugs. Adv. Drug Deliv. Rev. 5, 209-230.
117. [117] Hu, Y.P., Toulme, N., Bennis, S. and Robert, J. (1994) Doxorubicin encapsulation in liposomes and nanospheres for the reversal of multidrug resistance in vitro [abstract]. Anticancer Drugs, 37-38.
118. [118] Kreuter, J., Wilson, C.G., Fry, J.R., Paterson, P. and Ratcliffe, J.H. (1984) Toxicity and association of polycyanoacrylate nanoparticles with hepatocytes. J. Microencapsulation 1, 253-257.
119. [119] Kreuter, J. and Hartmann, H.R. (1983) Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. Oncology 40, 363-366.
120. [120] Verdun, C., Brasseur, F., Vranckx, H., Couvreur, P. and Roland, M. (1990) Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26, 13-18.
121. [121] Beck, P., Kreuter, J., Reszka, R. and Fichtner, I. (1993) Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. J. Microencapsulation 10, 101-114.
122. [122] Bornschein, M., Melegari, P., Bismarck, C. and Keipert, S. (1989) Micro-and nanopanicles as carrier systems with special consideration of the preparation methods. Pharmazie 44, 585-93.
123. [123] Simeonova, M., Ilarionova, M., Ivanova, T., Konstantinov, C. and Todorov, D. (1991) Nanoparticles as drug carriers for vinblastine. Acute toxicity of vinblastinein a free form and associated to polybutylcyanoacrylate nanoparticles. Acta Physiol. Pharmacol. Bulg. 17, 43-49.
124. [124] Colin de Verdiere, A., Dubernet, C., Nemati, F., Poupon, M.F., Puisieux, F. and Couvreur, P. (1994) Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother. Pharmacol. 33, 504-508.
125. [125] Bogush, T.A., Smirnova, G.B., Shubina, I., Bogush, E.A. and Robert, J. (1994) Intracellular accumulation of free doxorubicin and doxorubicin encapsulated in nanospheres. Biull. Eksp. Biol. Med. 118, 406-409.
126. [126] Guise, V., Jaffray, P., Delattre, L. Puisieux, F., Adolphe, M. and Couvreur, P. (1987) Comparative cell uptake of propidium iodide associated with liposomes or nanoparticles. Cell. Mol. Biol. 33, 397-405.
127. [127] Chavany, C., Saison, B.T., Le, D.T., Puisieux, F., Couvreur, P. and Helene, C. (1994) Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11, 1370-1378.
128. [128] Chavany, C., Le, D.T., Couvreur, P., Puisieux, F. and Helene, C. (1992) Polyalkylcyanoacrylate nanoparticles aspolymeric carriers for antisense oligonucleotides. Pharm. Res. 9, 441-449.
129. [129] Godard, G., Boutorine, A.S., Saison, B.E. and Helene, C. (1995) Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. Eur. J. Biochem. 232, 404-410.
130. [130] Schwab, G., Chavany, C., Duroux, I., Goubin, G., Lebeau, J., Helene, C. and Saison, B.T. (1994) Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA 91, 10460-10464.
131. [131] Venier-Julienne, M.C., Vouldoukis, I., Monjour, L. and Benoit, J.P. (1995) In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J. Drug Target. 3, 23-29.
132. [132] Gaspar, R., Opperdoes, F.R., Preat, V. and Roland, M. (1992) Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann. Trop. Med. Parasitol. 86, 41-49.
133. [133] Gaspar, R., Preat, V., Opperdoes, F.R. and Roland, M. (1992) Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm. Res. 9, 782-787.
134. [134] Chiannilkulchai, N., Driouich, Z., Benoit, J.P., Parodi, A.L. and Couvreur, P. (1989) Nanoparticles of doxorubicin: colloidal vectors in the treatment of hepatic metastases in animals. Bull. Cancer (Paris) 76, 845-8.
135. [135] Chiannilkulchai, N., Ammoury, N., Caillou, B., Devissaguet, J.P. and Couvreur, P. (1990) Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol. 26, 122-126.
136. [136] Kreuter, J. (1991) Liposomes and nanoparticles as vehicles for antibiotics. Infection, S224-S228.
137. [137] Liance, M., Nemati, F., Bories, C. and Couvreur, P. (1993) Experience with doxorubicin-bound polyisohexylcyanoacrylate nanoparticles on murine alveolar echinococcosis of the liver. Int. J. Parasitol. 23, 427-429.
138. [138] Pinto-Alphandary, H., Balland, O., Laurent, M. andremont, A., Puisieux, F. and Couvreur, P. (1994) Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium. Pharm. Res. 11, 38-46.
139. [139] Fattal, E., Rojas, J., Roblot, T.L., Andremont, A. and Couvreur, P. (1991) Ampicillin-loaded liposomes and nanoparticles: comparison of drug loading, drug release and in vitro antimicrobial activity. J. Microencapsulation 8, 29-36.
140. [140] Balland, O., Pinto, A.H., Pecquet, S., Andremont, A., and Couvreur, P. (1994) The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. J. Antimicrob. Chemother. 33, 509-522.
141. [141] Leroux, J.C., Gravel, P., Balant, L., Volet, B., Anner, B.M., Allemann, E., Doelker, E. and Gurny, R. (1994) Internalization of poly(D,L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles. J. Biomed. Mater. Res. 28, 471-481.
142. [142] Leroux, J.C., De, J.F., Anner, B., Doelker, E. and Gurny, R. (1995) An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. Life Sci. 57, 695-703.
143. [143] Schafer, V. von, B.H., Rubsamen, W.H., Steffan, A.M., Royer, C. and Kreuter, J. (1994) Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages. J. Microencapsulation 11, 261-269.
144. [144] Rolland, A., Merdrignac, G., Gouranton, J., Bourel, D., Le, V.R. and Genetet, B. (1987) Flow cytometric quantitative evaluation of phagocytosis by human mononuclear and polymorphonuclear cells using fluorescent nanoparticles. J. Immunol. Methods 96, 185-193.
145. [145] Schafer, V., von, B.H., Bender, A., Kreuter, J. and Rubsamen, W.H. (1993) Inhibition of HIV infection in vitro by antiviral drug targeting using nanoparticles [abstract]. Int. Conf. Aids, 9, 229, no. PO-A25-0565.
146. [146] Bender, A., Schfer, V., Steffan, A.M., Royer, C., Kreuter, J., Rubsamen, W.H. and von Briesen, H. (1994) Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res. Virol. 145, 215-220.
147. [147] Manil, L., Davin, J.C., Duchenne, C., Kubiak, C., Foidart, J., Couvreur, P. and Mahieu, P. (1994) Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro. Pharm. Res. 11, 1160-1165.
148. [148] Maincent, P., Thouvenot, P., Amicabile, C., Hoffman, M., Kreuter, J., Couvreur, P. and Devissaguet, J.P. (1992) Lymphatic targeting of polymeric nanoparticles after intrapentoneal administration in rats. Pharm. Res. 9, 1534-1539.
149. 14C]methacrylate nanoparticles after intravenous injection in rats. J. Pharm. Sci. 73, 1433-1437.
150. [150] Moghimi, S.M., Hawley, A.E., Christy, N.M., Gray, T., Illum, L. and Davis, S.S. (1994) Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett. 344, 25-30.
151. [151] Bazile, D., Prud'homme, C., Bassoullet, M.T., Marlard, M., Spenlehauer, G. and Veillard, M. (1995) Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84, 493-498.
152. [152] Borchard, G. and Kreuter, J. (1993) Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. J. Drug. Target. 1, 15-9.
153. [153] Stolnik, S., Dunn, S.E., Garnett, M.C., Davies, M.C., Coombes, A.G., Taylor, D.C., Irving, M.P., Purkiss, S.C., Tadros, T.F., Davis, S.S. and Illum, L. (1994) Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol)copolymers. Pharm. Res. 11, 1800-1808.
154. [154] Tan, J.S., Butterfield, D.E., Voycheck, C.L., Caldwell, K.D. and Li, J.T. (1993) Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. Biomaterials 14, 823-833.
155. 14C-poly(methyl methacrylate)nanoparticles. J. Microencapsulation 9, 19-28.
156. [156] Gref, R., Minamitake, Y., Peracchia, M.T., Trubetskoy, V., Torchilin, V. and Langer, R. (1994) Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603.
157. [157] Kreuter, J. and Liehl, E. (1981) Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. J. Pharm. Sci. 70, 367-71.
158. [158] Stieneker, F., Kreuter, J. and Lower, J. (1991) High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS 5, 431-435.
159. [159] Desai, M., Labhasetwar, V., Song, S., Qu, X., Amidon, G. and Levy, R. (1995) Uptake of microparticles by gut associated lymphoid tissue. Pharm. Res. 12, S233.
160. 14C,2-hydroxyethylmethacrylate, butylacrylate) nanoparticles after peroral administration to rats. Pharmazie 44, 339-340.
161. [161] Bodmeier, R., Chen, H.G. and Paeratakul, O. (1989) A novel approach to the oral delivery of micro-or nanoparticles. Pharm. Res. 6, 413-417.
162. [162] Florence, A.T., Hillery, A.M., Hussain, N. and Jani, P.U. (1995) Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target. 3, 65-70.
163. [163] Jani, P., Halbert, G.W., Langridge, J. and Florence, A.T. (1989) The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol. 41, 809-812.
164. [164] De Keyser, J.L., Poupaert, J.H. and Dumont, P. (1991) Poly(diethyl methylidenemalonate) nanoparticles as a potential drug carrier: preparation, distribution and elimination after intravenous and peroral administration to mice. J. Pharm. Sci. 80, 67-70.
165. [165] Nefzger, M., Kreuter, J., Voges, R., Liehl, E. and Czok, R. (1984) Distribution and elimination of polymethylmethacrylate nanoparticles after peroral administration to rats. J. Pharm. Sci. 73, 1309-1311.
166. [166] Pimienta, C., Lenaerts, V., Cadieux, C., Raymond, P., Juhasz, J., Simard, M.A. and Jolicoeur, C. (1990) Mucoadhesion of hydroxypropylmethacrylate nanoparticles to rat intestinal ileal segments in vitro. Pharm. Res. 7, 49-53.
167. [167] Scherer, D., Mooren, F.C., Kinne, R.K. and Kreuter, J. (1993) In vitro permeability of PBCA nanoparticles through porcine small intestine. J. Drug Target. 1, 21-27.
168. [168] Maincent, P., Le Verge, R., Sado, P., Couvreur, P. and Devissaguet, J.P. (1986) Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J. Pharm. Sci. 75, 955-958.
169. [169] Harmia, T., Speiser, P. and Kreuter, J. (1986) A solid colloidal drug delivery system for the eye: encapsulation of pilocarpin in nanoparticles. J. Microencapsulation 3, 3-12.
170. [170] Harmia, T., Speiser, P. and Kreuter, J. (1987) Nanoparticles as drug carriers in ophthalmology. Pharm. Acta Helv. 62, 322-331.
171. [171] Li, V.H., Wood, R.W., Kreuter, J., Harmia, T. and Robinson, J.R. (1986) Ocular drug delivery of progesterone using nanoparticles. J. Microencapsulation 3, 213-218.
172. [172] Losa, C., Calvo, P., Castro, E., Vila, J.J. and Alonso, M.J. (1991) Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J. Pharm. Pharmacol. 43, 548-552.
173. [173] Guo, C.Y., Shankar, R.R., Abe, S., Ye, Z., Thomas, R.N. and Kuo, J.E. (1992) Functionalized, probe-containing, latex nanospheres. Anal. Biochem. 207, 241-248.
174. [174] Macklis, J.D. and Quattrochi, J.J. (1991) Restricted diffusion and stability of carbachol-fluorescent nanospheres in-vivo. Neuroreport 2, 247-250.
175. [175] Pouliquen, D., Le, J.J., Perdrisot, R., Ermias, A. and Jallet, P. (1991) Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn. Reson. Imaging 9, 275-283.
176. [176] Nilsson, K.G. (1989) Preparation of nanoparticles conjugated with enzyme and antibody and their use in heterogeneous enzyme immunoassays. J. Immunol. Methods 122, 273-277.
177. [177] Kreuter, J., Alyautdin, R.N., Kharkevich, D.A. and Ivanov, A.A. (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles(nanoparticles). Brain Res. 674, 171-174.
178. [178] Cappel, M.J. and Kreuter, J. (1991) Effect of nanoparticles on transdermal drug delivery. J. Microencapsulation 8, 369-374.
179. [179] de Vringer, T. and de Ronde, H. (1995) Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J. Pharm. Sci. 84, 466-472.
180. [180] Mitchel, J.F., Fram, D.B., Palme, D., Foster, R., Hirst, J.A., Azrin, M.A., Bow, L.M., Eldin, A.M., Waters, D.D. and McKay, R.G. (1995) Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system, in vitro, in vivo, and clinical studies. Circulation 91, 785-793.
181. [181] Wilensky, R.L., March, K.L., Gradus, P.I., Schauwecker, D., Michaels, M.B., Robinson, J., Carlson, K. and Hathaway, D.R. (1995) Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am. Heart. J. 129, 852-859.
182. [182] March, K.L., Mohanraj, S., Ho, P.P., Wilensky, R.L. and Hathaway, D.R. (1994) Biodegradable microspheres containing a colchicine analogue inhibit DNA synthesis in vascular smooth muscle cells. Circulation 89, 1929-1933.
183. [183] Wilensky, R.L., March, K.L. and Hathaway, D.R. (1991) Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am. Heart J. 122, 1136-1140.
184. [184] Rome, J.J., Shayani, V., Flugelman, M.Y., Newman, K.D., Farb, A., Virmani, R. and Dichek, D.A. (1994) Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler. Thromb. 14, 148-161.
185. [185] Labhasetwar, V., Song, C., Humphrey, W., Shebuski, R. and Levy, R.J. (1995) Nanoparticles for site specific delivery of U-86983 in Restenosis in pig coronary arteries. Proc. Int. Symp. Control. Release Bioact. Mater., 22, 182-183.
186. [186] Song, C., Labhasetwar, V., Guzman, L., Topol, E. and Levy, R.J. (1995) Dexamethasone-nanoparticles for intra-arterial localization in restenosis in rats. Proc. Int. Symp. Control. Release Bioact. Mater. 22, 444-445.
187. [187] Song, C., Labhasetwar, V., Murphy, H., Qu, X., Humphrey, W.R., Shebuski, R.J. and Levy, R.J. (1997) Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J. Control. Release, in press.
188. [188] Guzman, L.A., Labhasetwar, V., Song, C., Jang, Y. and Levy, R.J. (1995) Single intraluminal infusion of biodegradable polymeric nanoparticles matrixed with dexamethasone decreases neointimal formation after vascular injury [abstract]. Circulation 92, 1-292.
189. [189] Guzman, L., Labhasetwar, V., Song, C., Jang, Y., Lincoff, M.A., Levy, R.J. and Topol, E.J. (1996) Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 94, 1441-1448.
190. [190] Eccleston, D.S., Furst, J., Labhasetwar, V., Levy, R.J. and Lincoff, A.M. (1995) Local delivery of polymeric nanospheres containing heparin reduces platelet deposition in the porcine balloon injury model [abstract]. Circulation, 92, 1-670.
191. [191] Wolinsky, H. (1994) Local delivery: let's keep our eyes on the wall [editorial comment]. J. Am. Coll. Cardiol. 24, 825-827.